Biotech Startups

NewLimit

Developing epigenetic therapies to extend human healthspan by reprogramming aging cells Biotech Healthcare

Last round: Series B Founders Fund, $130M Series B in 2025

ROME Therapeutics

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome. Biotech Healthcare Pharmaceuticals

Last round: Series B Andreessen Horowitz, $50M Series B in 2021, $70M valuation

Hoxton Farms

Grow real animal fat without the animals for delicious, cruelty-free, sustainable ingredient Biotech Sustainability

Last round: Series A Founders Fund, $22M Series A in 2022

Kernel

Kernel is a neuroscience company that specializes in developing brain-recording technologies. Biotech Life Science

Last round: Series C Khosla Ventures, $153M Series C in 2020

Synchron

Restore lives by deciphering the neural code of the brain Biotech Healthcare Hardware

Last round: Series C Khosla Ventures, $75M Series C in 2022

Clear Labs

Clear Labs is a provider of a fully-automated sequencing platform for turnkey diagnostics. Biotech Healthcare Robotics Hardware

Last round: Series C Khosla Ventures, $58M Series C in 2020

BioAge Labs

BIOAGE targets aging to develop drugs that treat severe diseases Biotech

Last round: Series D Andreessen Horowitz, $170M Series D in 2024

Karius

Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions. Biotech Genetics Healthcare

Last round: Series B Khosla Ventures, $165M Series B in 2020

CAMP4 Therapeutics

BioTech. Solving how genes are controlled to drive the efficient development of treatments. Biotech

Last round: Series B Andreessen Horowitz, $100M Series B in 2022